James Brumley

James Brumley

InvestorPlace Feature Writer

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Now That the Vivus Dust Has Settled …

By James Brumley, InvestorPlace Feature Writer

The diet-drug maker deserves a second -- more optimistic -- look after the hype and unmeetable expectations have passed.

‘.Money’: New Website Names Open a Door of Opportunity

By James Brumley, InvestorPlace Feature Writer

Verisign looks like the most straightforward beneficiary when the Internet opens the doors to new web address suffixes, but there are a few other potential winners.

Lampert Is Sears’ CEO? Here We Go Again

By James Brumley, InvestorPlace Feature Writer

Eddie Lampert's ascent to the helm of Sears Holdings should scare anyone that was banking on a turnaround at the struggling retailer.

Molycorp as a Buyout Target? Don’t Laugh.

By James Brumley, InvestorPlace Feature Writer

While some might chuckle at suggestions that Molycorp could be a buyout candidate, it's not all that unthinkable. But that doesn't mean you should buy MCP.

Bond Rating Agencies Quietly, Finally Forced Into Reform

By James Brumley, InvestorPlace Feature Writer

The state of New York might be meaningfully changing the game by holding credit rating companies responsible for their ratings.

Did Netflix’s Hastings Earn a Payday Doubler?

By James Brumley, InvestorPlace Feature Writer

Reed Hastings' big-time pay hike isn't as outlandish in size as many critics might suggest ... but the timing sure is crappy.

Spinoff Mania Is Winding Down (And Good Riddance!)

By James Brumley, InvestorPlace Feature Writer

Sooner rather than later, investors will wake up to the reality of the spinoff boom: These deals aren't all "unlocking value."

5 Mutual Funds to Buy for 2013

By James Brumley, InvestorPlace Feature Writer

Simplify at least part of your portfolio by picking some solid mutual funds in the coming year. Here are five promising names to consider.

Is the Russell 2000 Fund a Pointless ETF?

By James Brumley, InvestorPlace Feature Writer

In recent years, the archetype iShares Russell 2000 Index ETF hasn’t shown any stronger returns than its large-cap counterpart, the SPDR S&P 500 ETF.

Which Abbott Is the One to Own Post-Split?

By James Brumley, InvestorPlace Feature Writer

Both offer good prospects, but if you can choose just one, AbbVie -- which is the device and diagnostics side -- looks a tad more promising than the pharma arm.

Load More